CJC-1295 and Ipamorelin: Two Compounds, Open Questions
The Short Version: CJC-1295 Pairing Relies on Indirect Findings
The compound CJC-1295 prompts growth hormone release; ipamorelin is a separate compound with a similar aim. Here you'll learn why researchers pair the compounds and what remains untested.
No dedicated published human trial has tested CJC-1295 with ipamorelin. The 40,500 monthly searches counted for the pair show interest rather than improvements in anyone's health.
CJC-1295 acts on growth hormone cells in the gland beneath the brain [12]. Ipamorelin prompts the same gland through a different process inside those cells [5].
Researchers expect those two actions together might cause a larger hormone rise. That expectation hasn't been confirmed in a human trial of this CJC-1295 pair.
A volunteer study tested GHRP-2, another compound that prompts growth hormone release, with the body's growth hormone releasing hormone [7]. The study compared each compound alone against both together; pairing increased hormone release more [7].
Those volunteers didn't receive CJC-1295 with ipamorelin, so the comparison can't establish this pair's benefit. You can ask whether a claim names the compounds actually given to people.
In animals, ipamorelin testing found growth hormone rises without clear rises in cortisol, a hormone that helps the body handle stress [5]. The hormone that prompts cortisol and the hormone that supports milk production didn't clearly rise either.
Researchers first found the amount of ipamorelin that gave half the largest growth hormone rise. They tested amounts as high as 200 times that starting amount without clearly raising those other hormones.
That finding helps explain interest in ipamorelin, but doesn't establish the pair's safety. I'd ask your doctor what benefit might justify a pairing and what follow-up, visits, blood tests, time, and cost the proposed care would involve for your particular health concern.
CJC-1295 Pairing Claims Use Studies of Other Treatments
Small human reports haven't established health benefits from CJC-1295 with ipamorelin [5][10][11]. The studies discussed below tested other treatments, leaving the CJC-1295 pair itself unproved for you.
Tesamorelin is a separate compound that prompts growth hormone release. In people with unusual belly fat buildup, deep belly fat fell about 18% by twelve months [9].
Rats given a steroid that slowed bone growth were studied with ipamorelin alone [10]. Their outer bone growth was four times greater than in rats receiving only the steroid.
The rats received 100 micrograms per kilogram three times daily for three months. A gram split into a million equal parts gives one microgram; those study amounts don't choose an amount for you.
A seven-day rat study used prednisolone, a steroid medicine that caused the rats to lose protein [11]. Tests found rats given ipamorelin kept more protein, about as much as rats given growth hormone.
That result doesn't prove the rats grew stronger or that the pair would help your muscles. You'd need human testing of CJC-1295 with ipamorelin to answer those health questions.
CJC-1295 Lasts Longer Than Ipamorelin in Blood
No human CJC-1295 trial has established the best timing for giving both compounds. Reports describe shots beneath the skin, but don't establish a plan for your treatment.
In healthy volunteers, half the ipamorelin left blood in about 2 hours [6]. The strongest growth hormone rise happened earlier than that.
CJC-1295 with DAC, its added part, remains in blood for days [1]. Ipamorelin might briefly raise growth hormone further while the CJC-1295 response is still lasting.
That possibility doesn't establish how large or how long a paired response would be. You can ask which form of CJC-1295 was used and what was actually measured.
Meals and sleep also change growth hormone release, making comparisons harder. Higher blood sugar can weaken the response, so researchers consider food when measuring hormone changes [1][3].
Human Reports Don’t Establish Muscle Gains for This Pair
Reports in people are few and mostly describe experiences during use. Those aren't large, long CJC-1295 trials that can establish a muscle benefit for you.
Related pairs preserved muscle and reduced fat in rats and mice. Growth hormone and the growth-related hormone from the liver help explain why those changes are studied.
Human testing used tesamorelin, a different compound, and found less deep belly fat at six months. The reduction was about 18% at twelve months [9], leaving this pair's effect untested.
The 2026 review also found less liver fat in tesamorelin studies [21]. Those results can't establish what CJC-1295 with ipamorelin would do for your weight or strength.
CJC-1295 Partners May Raise Different Hormones
GHRP-2 and ipamorelin are separate compounds studied for prompting growth hormone release. With related compounds, GHRP-2 can cause larger growth hormone bursts [7].
Studies of that compound in animals and people also found rises in cortisol, the body's stress hormone. The hormone that tells the body to make cortisol rose as well.
Animal testing of ipamorelin didn't find clear rises in those hormones or the hormone supporting milk production [5]. Researchers first measured the amount that gave half the largest growth hormone rise.
Even at 200 times that starting amount, ipamorelin didn't clearly raise those other hormones. That finding concerns ipamorelin alone, rather than safety testing of a CJC-1295 pairing.
At amounts causing similar growth hormone rises, ipamorelin changed fewer other hormones than GHRP-2. You can't infer which pair would benefit your health from that difference alone.
CJC-1295 with Ipamorelin Lacks a Direct Comparison With MK-677
No direct human trial has compared MK-677 with CJC-1295 ipamorelin [20]. MK-677 is a compound tested as a pill, rather than one given by shot.
The swallowed compound is also called ibutamoren and isn't a peptide. At 25 milligrams daily in testing, growth-related hormones stayed raised across a 24-hour period.
CJC-1295 with ipamorelin uses shots and is expected to prompt growth hormone bursts. The ways of giving these compounds, timing of hormone rises, and reported problems differ.
Those differences don't show which approach would improve your health. Ask your doctor whether a claimed CJC-1295 advantage was measured in a direct human comparison.
CJC-1295 Pairing Risks Are Expected Rather Than Measured
A published human trial hasn't measured side effects from both compounds together. Concerns about greater swelling, flushing, and shot reactions rely on findings about CJC-1295 alone [13].
A larger growth hormone rise might cause more swelling by making the kidneys keep salt. Water stays with the salt, but the added risk from pairing hasn't been measured [8].
The Teichman 2006 trial used only the longer-lasting form, leaving the pair's reaction rates unknown. About 23% had redness at the shot site, and about 22% had brief flushing or dizziness [13].
Those figures don't tell you how often reactions would happen with both compounds. At your visit, ask which concerns were measured and which are expected from the compounds' actions.